- Location
adjunctive treatment
"-
Omeros Corporation Announced Positive Results From a Phase 2A Clinical Trial of OMS824
Feb 7, 2014Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic ...
-
FDA Approved Sunovion AED Aptiom for The Treatment of Partial-Onset Seizures in Patients
Nov 12, 2013The US Food and Drug Administration (FDA) has approved Sunovion Pharmaceuticals' (Sunovion) antiepileptic drug (AED) Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures in patients with epilepsy. According to the ...
Tags: FDA, Sunovion, partial-onset seizure, epilepsy
-
Lundbeck Has Obtained The US FDA Approval for Its SABRIL
Oct 30, 2013Lundbeck, a Denmark-based pharmaceutical company, has obtained the US Food and Drug Administration (FDA) approval for its SABRIL (vigabatrin), an adjunctive treatment option for children 10 and older with refractory complex partial ...
-
Health Canada Has Accepted to Review Sunovion Pharmaceuticals Canada's NDS
Sep 19, 2013Health Canada has accepted to review Sunovion Pharmaceuticals Canada's (Sunovion) new drug submission (NDS) for eslicarbazepine acetate for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients aged ...
-
Kinetic Concepts Launched V.A.C. VeraFlo for Larger Wounds and Wounds
Aug 15, 2013Kinetic Concepts has launched its new V.A.C. VeraFlo large dressing for larger wounds and wounds requiring additional c. VeraFlo large dressing is designed for easy application of V.A.C. VeraFlo instillation therapy. With this ...
Tags: Kinetic, Dressing Product
-
Neurosigma Received IDE Approval From FDA
Jul 31, 2013NeuroSigma has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a Phase III pivotal trial of its Monarch eTNS System. Designed to treat the drug resistant epilepsy, the ...
Tags: Device Trial, NeuroSigma
-
Patients with Negative Pressure Wound Therapy Benefits Make The Kcl Trigger Evaluation
Jun 25, 2013Medical technology company Kinetic Concepts (KCI) has initiated patient enrollment in a multi-center clinical study that will assess the advantages of negative pressure wound therapy (NPWT) with intermittent instillation therapy with a ...
Tags: Health, Medicine, Medical technology
-
Eisai Received Positive Opinion From European Medicines Agency's Committee for Fycompa
Dec 5, 2012Eisai has received positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Fycompa (perampanel), an AMPA receptor antagonist. Fycompa (perampanel) is an adjunctive treatment of ...
Tags: fycompa, perampanel, epilepsy, zonisamide
-
Sagent Pharmaceuticals Has Introduced Acetazolamide for Injection
Nov 28, 2012Sagent Pharmaceuticals has introduced Acetazolamide for Injection, USP specified for adjunctive treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies and chronic simple glaucoma, secondary ...
Tags: Acetazolamide Injection, adjunctive treatment, Pharmaceuticals
-
FDA Has Approved Eisai's Non-Competitive AMPA Glutamate Receptor
Oct 24, 2012The US Food and Drug Administration (FDA) has approved Eisai's non-competitive AMPA glutamate receptor antagonist for patients who continue to have seizures despite being on other prescription medications for epilepsy. The drug, ...
-
Qualitest Pharmaceuticals Wins The US FDA Approval of Qualitest Levetiracetam ANDA
Jul 26, 2012Qualitest Pharmaceuticals, a generic pharmaceutical company, has won the US Food and Drug Administration (FDA) approval for abbreviated new drug application (ANDA) for Levetiracetam extended-release tablets, 500mg and 750mg. The ...
